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Introduction {#sec1.1}
------------

Eukaryotic cells degrade proteins with two main hydrolytic machineries, proteasomes and lysosomes. In both systems, catabolic activities are physically separated from intracellular substrates---in proteasomes, by localization in a barrel-shaped multiprotein complex and in lysosomes, by its vesicular membrane. Therefore, access to the hydrolytic activities within these structures determines whether a protein is degraded. For proteasomes, polyubiquitination allows substrates to gain access to the catalytic chamber for proteolysis ([@bib19]). For lysosomes, autophagy delivers intracellular constituents for degradation, but how autophagosome cargo is selected remains unclear ([@bib23]). Although proteasomes degrade soluble short-lived proteins, autophagy targets cell organelles and aggregates of long-lived proteins for degradation ([@bib41]).

Autophagy is composed of at least three distinct pathways: microautophagy, chaperone-mediated autophagy, and macroautophagy ([@bib67]). Microautophagy involves budding of small cytosol-containing vesicles, and this budding occurs directly into the lysosomal lumen. During chaperone-mediated autophagy, proteins are directly imported into lysosomes via the LAMP-2a transporter ([@bib20], [@bib21]) assisted by cytosolic ([@bib17]) and lysosomal ([@bib2]) HSC70 chaperones. Substrates of chaperone-mediated autophagy carry signal peptides for sorting into lysosomes, similar to other protein-transport mechanisms across membranes ([@bib1]). Finally, during macroautophagy, a cup-shaped isolation membrane forms de novo from sources that are still debated ([@bib48]). In this process, cytosolic constituents are enclosed in a double-membrane vesicle, called autophagosome ([@bib31], [@bib96]), which then fuses with lysosomes and late endosomes for degradation of the inner autophagosomal membrane and its cargo ([@bib75]) ( [Figure 1](#fig1){ref-type="fig"}). The class III phosphatidylinositol 3-kinase (PI3K) and its binding partner, the autophagy-related gene (Atg) 6 (also known as Beclin-1), is required for the initiation of the isolation membrane ([@bib50], [@bib104]). In addition, two ubiquitin-like systems are essential for the formation of autophagosomes: In one of them, the five C-terminal amino acids of the ubiquitin-like protein Atg8 (also known as light chain \[LC\] 3) are cleaved off by the Atg4 protease to liberate a glycine residue (G~120~). This C-terminal residue then gets transferred to phosphatidylethanolamine in the forming isolation membrane by the E1- and E2-like enzymes Atg7 and Atg3. Although Atg8 (LC3) gets recycled from the outer autophagosomal membrane by deconjugation from the phospholipid, it remains attached to the inner autophagosomal membrane, and this proportion is degraded with the inner autophagosomal membrane in lysosomes and late endosomes after fusion with these vesicles ([@bib44], [@bib49]). In the other ubiquitin-like system, Atg12 gets coupled via its C-terminal glycine residue (G~140~) to a lysine residue of Atg5 by the E1- and E2-like enzymes Atg7 and Atg10. The Atg12-Atg5 complex associates with Atg16 and then binds to the outer surface of the isolation membrane. Upon completion of the autophagosome, the Atg5-Atg12-Atg16 complex dissociates from the outer autophagosomal membrane ([@bib68]).Figure 1Molecular Machinery of MacroautophagyAtg6 (Beclin-1) is part of the type III PI3K complex that initiates autophagosome formation. Two ubiquitin-like systems are required for formation of the isolation membrane and couple Atg8 (LC3) and Atg12 to phosphatidylethanolamine (PE) and Atg5, respectively. The five C-terminal amino acids of Atg8 (LC3) are cleaved of by Atg4 to reveal glycine 120 (G~120~), which is required to link the protein after activation by Atg7 and ligation by Atg3 to PE in the autophagosomal membrane (green circles). Similarly, glycine 140 (G~140~) is used by Atg7 and Atg10 to couple Atg12 to Atg5. This complex then localizes to the outer membrane of the forming autophagosome (blue squares). Upon autophagosome completion, the Atg12-Atg5 complex recycles from the outer membrane, and only Atg8 (LC3) remains associated with the completed autophagosome. Autophagosomes then fuse with late endosomes and lysosomes for degradation of their cargo and their intravesicular membranes.

The exact functions of the components of the molecular machinery for macroautophagy are not well understood to date. Because the Atg5-Atg12-Atg16 complex localizes to the convex surface of the isolation membrane, it may determine the curvature of the forming autophagosome through a protein lattice, not unlike what clathrin coating does for endosomes ([@bib101]). Furthermore, because Atg8 (LC3) is primarily localized to the inner autophagosomal membrane, especially after autophagosome completion, it was proposed that this molecule could serve as an anchor for autophagy substrates. Two proteins, Alfy and p62 (also known as SQSTM1), have been suggested for the targeting of proteins to autophagosomes ([@bib13], [@bib92]). Alfy has been found in proximity to autophagic membranes and colocalizing with protein aggregates under conditions of starvation and proteasome inhibition, which are known to upregulate macroautophagy ([@bib67], [@bib92]). Similarly, p62 (SQSTM1) has been found to localize to protein aggregates, is degraded by macroautophagy, and could be coimmunoprecipitated with Atg8 (LC3) ([@bib13]). Both proteins were suggested to target protein aggregates to autophagosomes, in the case of p62 (SQSTM1) by binding to Atg8 (LC3).

These studies on the molecular mechanisms of autophagy and its importance in protein metabolism have set the stage to analyze its importance during immune responses. In the following sections, we will discuss autophagy during innate immune responses to viruses, bacteria, and parasites and highlight its role in the initiation and execution of adaptive immune responses.

Escape from Autophagy by Viruses {#sec1.2}
--------------------------------

Viral immune escape from proteasomal degradation has been characterized in great detail ([@bib100]). In contrast, the interaction between viruses and the autophagic machinery is just beginning to be elucidated. The three following main outcomes of these interactions have been noted: Macroautophagy successfully limits viral replication, viruses inhibit macroautophagy to avoid restriction of their replication, or viruses use accumulated autophagosomes for their replication ( [Figure 2](#fig2){ref-type="fig"}).Figure 2Innate Immune Control by MacroautophagyViruses, bacteria, and parasites get cleared or interfere with their destruction by macroautophagy. Herpesviruses encode inhibitors of autophagosome formation, whereas picornaviruses and coronaviruses inhibit fusion of autophagosmes with lysosomes in order to replicate on autophagosomal membranes. *Rickettsia conorii* and group A *Streptococcus*, examples of bacterial pathogens that escape the endosome, are degraded by macroautophagy, but *Shigella flexneri* has developed an escape strategy that avoids its import into autophagosomes. *Brucella abortus* and *Legionella pneumophila* block autophagosome-lysosome fusion and replicate in autophagic vesicles. Pathogens such as *Toxoplasma gondii* and *Mycobacterium tuberculosis* condition phagosomes as replication niches, which can be cleared by macroautophagy after immune activation of the host cell.

Only two studies have demonstrated so far that macroautophagy can successfully limit viral replication. One example comes from plant infection by the tobacco mosaic virus (TMV). This single-stranded RNA virus of the *Tobamovirus* family replicates more efficiently when Atg6 (Beclin-1) or Atg7 are silenced in *Nicotiana benthamiana* plants ([@bib62]). The second example is a single-stranded RNA virus of the *Togavirus* family. Sindbis virus of this virus family causes encephalitis, which can be ameliorated by overexpression of Atg6 (Beclin-1) in mice ([@bib58]). After virus-driven Atg6 (Beclin-1) overexpression, less Sindbis virus RNA-positive cells, decreased brain pathology, and lower viral titers are detected in mice. Although the role of constitutive macroautophagy in Sindbis-virus-mediated encephalitis has not been elucidated so far, enhanced macroautophagy seems to confer protection against viral replication. Another protective role that macroautophagy seems to play during viral infections is to deliver pathogen constituents for detection by endosomal receptors that initiate immune responses, such as toll-like receptors (TLRs) ([@bib53]). One member of this family, TLR7, detects single-stranded RNA. In the case of vesicular stomatitis virus (VSV) and Sendai virus (SV) infection, TLR7-dependent activation of plasmacytoid dendritic cells (pDCs) and their type I IFN secretion seem to rely on macroautophagy because Atg5-deficient pDCs are unable to secrete IFN-α in response to SV and VSV infection. However, further studies are required to ensure that pDC function is not generally compromised in the absence of macroautophagy and to analyze to what extent this pathway contributes to the detection of viral infections in vivo.

In contrast to these examples of protection from viral infection via macroautophagy, two double-stranded DNA viruses of the herpesvirus family, herpes simplex virus-1 (HSV-1) and Kaposi\'s sarcoma-associated herpesvirus (KSHV), escape the fate of restriction or detection by macroautophagy via expression of inhibitors of this pathway. Both viruses target Atg6 (Beclin-1) for this purpose. HSV-1 expresses the early-antigen, infected cell protein 34.5 (ICP34.5), which inhibits macroautophagy and thereby allows increased viral replication in mouse embryonic fibroblasts ([@bib97]). Interestingly, recombinant HSV-1 with a mutant ICP34.5 protein that can no longer interact with Atg6 (Beclin-1) and thereby fails to inhibit macroautophagy is severely attenuated with respect to neurovirulence in mice ([@bib76]). This suggests that macroautophagy inhibition is essential for efficient replication of HSV-1 in the central nervous system of mice in vivo. Atg6 (Beclin-1) is also the target of macroautophagy inhibition by KSHV. Its Bcl-2 homolog binds to Atg6 (Beclin-1) and thus inhibits macroautophagy ([@bib78]), but it remains unclear whether this function is important for KSHV replication.

An even more dramatic subversion of macroautophagy is practiced by several single-stranded RNA viruses, which replicate in the cytoplasm. Picornaviruses (poliovirus and rhinoviruses), coronaviruses (mouse hepatitis virus and severe acute respiratory syndrome coronavirus), and one arterivirus (equine arteritis virus) replicate on the surface of autophagosomal membranes ([@bib22], [@bib46], [@bib79], [@bib81], [@bib82]). These viruses probably block the fusion of autophagosomes, which carry their replication complexes, with lysosomes. In the case of poliovirus and rhinoviruses, this macroautophagy regulation seems to be brought about by the 2BC and 3A proteins, which are sufficient to induce the accumulation of autophagosomes ([@bib46]). Generation of autophagic membranes as scaffolds for the replication machinery is essential because inhibition of macroautophagy by siRNA-mediated silencing of Atg12 or Atg8 (LC3) inhibits viral replication ([@bib46]). Therefore, a number of single-stranded RNA viruses interfere with autophagosome maturation in order to replicate on the surfaces of these vesicles. Similarly, to their benefit, the double-stranded RNA virus rotavirus of the reovirus family and the single-stranded DNA virus B19 parvovirus both induce macroautophagy, with rotavirus mediating this effect via its NSP4 protein ([@bib10], [@bib72]). Rotavirus seems to replicate in close proximity to autophagic membranes, and B19 parvovirus might prolong the survival of infected cells via macroautophagy. However, the exact function of macroautophagy induction by these two viruses is not entirely understood.

Although all viruses listed above regulate macroautophagy to promote their own replication, two other viruses use the molecular macroautophagy machinery differently for their benefit. Human immunodeficiency virus 1 (HIV-1) induces autophagy-dependent apoptosis or autophagic cell death in bystander CD4^+^ T cells when the envelope protein of HIV-1 interacts with the chemokine receptor CXCR4 on the cell surface of CD4^+^ T cells ([@bib30]). By these means, HIV-1 might deplete the CD4^+^ T cell compartment beyond destruction through viral replication. Another way in which a virus can benefit from the macroautophagy machinery is demonstrated by the single-stranded RNA virus bovine viral diarrhea virus (BVDV) of the flavivirus family. This virus has incorporated part of the Atg8 (LC3) sequence for specific proteolytic processing of its polyprotein ([@bib64]), presumably via the Atg4 protease, which liberates G~120~ of Atg8 (LC3) for coupling to autophagosomal membranes ([Figure 1](#fig1){ref-type="fig"}). In this fashion, the virus uses a specific proteolytic event of the macroautophagy machinery to process its protein products.

Thus, both viruses and their hosts have evolved various ways to utilize or subvert macroautophagy for their benefit. The many pathways by which viruses target this catabolic process suggest that it is important for innate immunity against these pathogens.

Autophagic Defense against Intracellular Bacteria and Parasites {#sec1.3}
---------------------------------------------------------------

In contrast to viruses, a number of microbial pathogens have been described to be successfully targeted by macroautophagy during innate immune responses. However, most of these studies have been performed in vitro, and it remains to be established whether macroautophagy can restrict bacteria and parasites in vivo.

Bacteria and parasites have been found to be susceptible to macroautophagy in two cellular compartments after entering their host cells. Free bacteria in the cytosol can fall prey to macroautophagy, and pathogen-conditioned phagosomes can either fuse with or get engulfed by autophagosomes ([Figure 2](#fig2){ref-type="fig"}). Group A *Streptococci* multiply freely in *atg5* ^−/−^ mouse embryonic fibroblasts after escaping from endosomes ([@bib71]). In contrast in wild-type cells, cytosolic group A *Streptococci* become enveloped by autophagosomes and are delivered for lysosomal hydrolysis. Similarly, the cytoplasmic bacterium *Rickettsia conorii* was observed in autophagosomal structures in endothelial cells by electron microscopy ([@bib102]). Proinflammatory cytokines lead to increased macroautophagy and *Rickettsia* clearance from the cytoplasm. However, it has not been conclusively shown that the protective cytokines required autophagy for restriction of *Rickettsia*. Furthermore, metabolic inhibition of *Listeria monocytogenes* after phagosome lysis renders these bacteria susceptible for macroautophagy and lysosomal clearance ([@bib87]). Engulfment of *Listeria* can be blocked by pharmacological autophagy inhibitors and accelerated by starvation. In addition to eliminating pathogens in the cytosol, macroautophagy can also target phagosomes that have been conditioned by bacteria or parasites to avoid fusion with lysosomes. The best-studied examples for these are *Mycobacterium tuberculosis* and *Toxoplasma gondii* ([@bib7], [@bib34], [@bib60]). *M. tuberculosis* was shown to be cleared from mouse macrophages and a human macrophage cell line by macroautophagy ([@bib34], [@bib93]). Starvation-induced clearance of the *M. tuberculosis* variant *bovis* BCG is inhibited by pharmacological inhibitors of macroautophagy. In addition to starvation, lipopolysaccharide (LPS)-induced autophagic clearance of *M. tuberculosis*-containing phagosomes via TLR4-TRIF-RIP1-p38MAPK signaling ([@bib103] \[this issue of *Immunity*\]) has been observed. An autophagy-dependent protective mechanism is the lysosomal generation of bactericidal peptides from ubiquitin after autophagic delivery of ubiquitinylated protein aggregates ([@bib3]). The induction of autophagy by starvation resulted in enhanced delivery of ubiquitinated proteins to microbacteria-harboring phagosomes and increased the bactericidal activity of lysosomes. Similarly, *T. gondii* appears to be susceptible to macroautophagic degradation in mouse and human macrophages ([@bib7], [@bib60]). Clearance of *T. gondii* tachyzoites upon macrophage activation could be inhibited by pharmacological inhibitors of macroautophagy and siRNA silencing of Atg6 (Beclin-1). Less well characterized is the macroautophagic degradation of *Salmonella enterica* and uropathogenic *Escherichia coli*-containing vacuoles ([@bib5], [@bib12]). However, *S. enterica* at least seems to stimulate macroautophagy via injection of its SipB protein into the cytosol through the bacterial type III secretion system ([@bib42]).

As summarized above for viruses, bacteria have also developed counteracting mechanisms against innate restriction by macroautophagy. Again, both autophagosome generation and maturation into autolysosomes are targeted ([Figure 2](#fig2){ref-type="fig"}). However, unlike viruses, these mechanisms do not seem to generally inhibit macroautophagy of the host cell in *trans* but rather prevent autophagic clearance of the particular bacterial pathogens in *cis*, without affecting the degradation of other autophagy substrates. *Shigella flexneri* inhibits macroautophagy, which is induced by the binding of its VirG protein to Atg5 ([@bib74]). This specific interaction of the autophagic machinery with a bacterial protein is disrupted by *Shigella*\'s IcsB protein, and loss of IcsB leads to autophagic clearance of these bacteria from the cytosol. A number of other bacterial and parasitic pathogens trigger macroautophagy for their efficient replication. Instead of using autophagosomal membranes as scaffolds for replication, as discussed above for single-stranded RNA viruses, they replicate most effectively inside autophagosomes and autolysosomes. Pathogens of this category include *Francisella tularensis*, *Brucella abortus*, *Porphyromonas gingivalis*, *Leishmania mexicana*, *Chlamydia trachomatis*, *Coxiella burnetii*, and *Legionella pneumophila* ([@bib4], [@bib6], [@bib15], [@bib16], [@bib29], [@bib36], [@bib80], [@bib89]). At least some of these bacteria use their type III and type IV secretion systems to trigger autophagy and also inhibit fusion of autophagosomes with lysosomes to generate their replication niche. For example, 10--30 kDa components of *Legionella* type IV secretion substrates are able to stimulate macroautophagy in mouse macrophages ([@bib6]). In contrast, the type IV secretion system of *Brucella* is required to prevent fusion of the vesicular *Brucella* replication compartment with lysosomes ([@bib15]). Establishment of this compartment can be inhibited by pharmacological inhibitors of macroautophagy ([@bib80]). Thus, by using their elaborate secretion systems, successful bacterial pathogens can subvert macroautophagy for their benefit, and therefore avoid autolysosomal degradation in their host cells.

Apart from pathogen clearance, macroautophagy provides another type of protection from bacterial pathogenesis during *Vibrio cholerae* infection. This noninvasive intestinal pathogen secretes the hemolytic exotoxin cytolysin, but gut epithelial cell lines resist cell death induced by this toxin through the induction of macroautophagy ([@bib35]). Atg5-deficient cells on the contrary displayed poor survival upon exposure to *Vibrio* cytolysin.

Thus, bacterial pathogens, both after escaping from endosomes into the cytosol and in phagosomes, can become substrates for macroautophagy. The efficiency of this innate immune defense mechanism most probably forced successful bacterial pathogens to develop escape mechanisms against autophagic degradation.

Antigen Presentation via Autophagy {#sec1.4}
----------------------------------

In addition to limiting pathogen replication in host cells, macroautophagy also delivers viral, parasitic, and bacterial antigens to late endosomal compartments, where macroautophagy substrates are then degraded by lysosomal hydrolases. The fusion vesicles between autophagosomes and late endosomes, the so-called amphisomes, have been isolated and ultrastructurally characterized by electron microscopy ([@bib9], [@bib61]). In these studies, double-membrane-enveloped autophagosomes receive colloidal gold after endocytosis, and the resulting amphisomes could be stabilized by inhibition of lysosomal degradation. The amphisomes display multivesicular and multilamellar morphology. Exactly the same characteristics have been reported for major histocompatibility complex (MHC) class II loading compartments (MIICs) ([@bib106]), which are now considered to be conventional late endosomes that are equipped with the molecular machinery to load antigenic fragments onto MHC class II molecules for presentation to CD4^+^ T cells.

We have recently shown that GFP-Atg8 (GFP-LC3)-positive autophagosomes fuse frequently with MIICs, as identified by the presence of MHC class II, the lysosomal membrane protein LAMP-2 and the chaperone HLA-DM, which is involved in peptide loading onto MHC class II molecules ([@bib90]). We observe 50%--80% overlap between Atg8 (LC3) and MHC class II in professional antigen-presenting cells, such as dendritic cells and B cell lines, as well as epithelial cell lines, in which MHC class II expression was induced by proinflammatory cytokines. This cell-biological evidence suggests that macroautophagy frequently delivers autophagosome content, including pathogen-derived proteins, to MIICs ( [Figure 3](#fig3){ref-type="fig"}).Figure 3Role of Macroautophagy in Adaptive Immune ResponsesAutophagic pathways can deliver antigens for MHC class II presentation. Autophagosomes and LAMP-2a, the transporter associated with chaperone-mediated autophagy, can transport antigens into the MHC-class-II-loading compartment (MIIC). In MIICs, the antigen is processed and loaded onto MHC class II molecules for CD4^+^ T cell stimulation. Activated CD4^+^ T cells can then in turn enhance macroautophagy and autophagosome-lysosome fusion via type II IFN and TNF family members (IFN-γ, TNF, TRAIL, and CD40L). In addition, Th2-polarized CD4^+^ T cells are susceptible to cell death by macroautophagy.

Biochemical isolation of natural MHC class II ligands reveals that up to 20% of eluted peptides originate from cytosolic and nuclear proteins ([@bib18], [@bib24], [@bib27], [@bib85]). Among them, two fragments of Atg8 (LC3) (MAP1LC3B~93-109~ and MAP1LC3B~93-110~) have been isolated from HLA-DR molecules of Epstein Barr virus (EBV)-transformed B cell lines ([@bib24]). Other sources of natural MHC class II ligands also fit the characteristics of autophagy substrates. Some long-lived proteins, which appear to be preferentially degraded by autophagy ([@bib41]), have been frequently found to give rise to MHC class II peptide cargo. For example, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) with the extraordinarily long half-life of 130 hr ([@bib25]) has been described as a substrate of chaperone-mediated autophagy ([@bib8]) and has been isolated from autophagosomes ([@bib32]). In good agreement with autophagic delivery of antigens for MHC class II loading, GAPDH-derived peptides have been isolated from four different MHC class II molecules, but no natural MHC class I ligands have been described from this protein so far ([@bib85]). In contrast, cyclins with half-lives in the order of minutes are one of the most frequent sources of MHC class I peptides and have been eluted from 17 different MHC class I molecules, but only one MHC class II ligand from this group of proteins has been described so far ([@bib85]). Short and long half-life correlate to some extent with the degradation route of proteins. For example, the nuclear antigen 1 of EBV (EBNA1) contains a glycine alanine (GA)-repeat domain, which inhibits its degradation via the proteasome and presentation on MHC class I ([@bib43], [@bib54], [@bib55], [@bib56]). EBNA1\'s half-life is very long ([@bib56], [@bib98]) but is shortened considerably upon deletion of the GA repeat ([@bib56]). GA-deleted EBNA1 is degraded by the proteasome and efficiently presented on MHC class I ([@bib54], [@bib56]). In contrast, long-lived wild-type EBNA1 is presented on MHC class II after macroautophagy ([@bib77]). Similarly, influenza matrix protein 1 (MP1) is intracellularly processed onto MHC class II ([@bib47]), but when the half-life of MP1 is shortened by N-end-rule modification with enhanced proteasomal degradation, endogenous MHC class II presentation is lost ([@bib33]).

Further evidence, consistent with the hypothesis that proteins with long half-lives are preferentially processed for MHC class II presentation, comes from analysis of the RAD23 protein. Not unlike EBNA1, this protein contains a domain that prevents proteasomal proteolysis ([@bib39]). Deletion of this UBA2 domain shortens RAD23\'s half-life and makes it more susceptible to proteasomal degradation. Interestingly, when autophagy is induced by starvation and then natural HLA-DR ligands are eluted, peptides derived from cytosolic and nuclear antigens are upregulated, whereas natural ligands from membrane and secreted proteins are not affected ([@bib24]). A protein whose MHC class II presentation is strongly upregulated after 24 hr of starvation is RAD23. Taken together, all these examples suggest that long-lived autophagy substrates are efficiently processed for MHC class II presentation to CD4^+^ T cells.

CD4^+^ T Cell Stimulation after Autophagy {#sec1.5}
-----------------------------------------

Direct involvement of the molecular machinery for autophagy in intracellular antigen presentation on MHC class II has been documented only for a few antigens so far. The first study implicating macroautophagy in antigen processing onto MHC class II demonstrated that pharmacological inhibition of autophagosome formation decreased MHC class II presentation of the overexpressed complement C5 protein in mouse macrophage and B cell lines ([@bib14]). In this study and many follow-up studies, inhibitors of the class III PI3 kinase complex, including 3-methyladenine ([@bib91]), have been used to inhibit macroautophagy. However, 3-methyladenine has additional effects on membrane trafficking such as endocytosis, on lysosomal acidification, on phosphorylation of some signal transduction molecules, and on mitochondrial permeability ([@bib66]). Therefore, pharmacological inhibition of macroautophagy can be used as a first indication that this pathway is involved, but this finding should be confirmed by RNA interference or in knockout cells. With these caveats of pharmacological inhibitors in mind, two additional studies have used those to implicate macroautophagy in intracellular MHC class II antigen processing of the tumor antigen Mucin gene 1 (MUC1) product ([@bib28]) and the model antigen neomycin phosphotransferease II (NeoR) ([@bib73]). Of these, the latter study controlled, as carefully as possible, for macroautophagy-independent side effects of the pharmacological inhibitors by demonstrating that CD8^+^ T cell recognition of the tumor antigen tyrosinase and MHC class II antigen processing of extracellular NeoR were not influenced by 3-methyladenine. In addition, NeoR accumulated intracellularly and was excluded from delivery to lysosomes by this treatment. Therefore, the authors provided good evidence that NeoR is delivered by macroautophagy for MHC class II presentation in EBV-transformed B cells and in renal cell carcinoma cells.

In addition to these studies on self, tumor, and model antigens, we have demonstrated that the viral antigen EBNA1 is processed intracellularly for MHC class II presentation to CD4^+^ T cells via macroautophagy in EBV-transformed B cells and EBNA1-transfected EBV-negative Hodgkin\'s lymphoma cells ([@bib70], [@bib77]). Upon inhibition of lysosomal degradation, we have found EBNA1 accumulating in autophagosomes, visualized as multiple membrane-enveloped vesicles or isolation membranes in electron microscopy. Furthermore, intracellular EBNA1 processing for MHC class II presentation is inhibited by siRNA-mediated silencing of the essential autophagy gene Atg12. According to these data, EBNA1 is the first antigen for which physiological amounts have been demonstrated to be processed onto MHC class II after macroautophagy. More recently, we have shown that targeting of influenza MP1 to autophagosomes by fusing this antigen to Atg8 (LC3) enhanced MHC class II presentation to MP1-specific CD4^+^ T cell clones 5- to 20-fold, whereas MHC class I presentation to MP1-specific CD8^+^ T cell clones was not affected by attachment to Atg8 (LC3) ([@bib90]). We have observed increased MP1-Atg8 (MP1-LC3) presentation on MHC class II in epithelial cells, EBV-transformed B lymphoblastoid cells, and dendritic cells. Targeting of the fusion antigen for MHC class II presentation is dependent on coupling of MP1-Atg8 (LC3) to the autophagosomal membrane because a mutant protein lacking the glycine residue (Gly~120~) used for the ubiquitin-like conjugation reaction does not show enhanced MHC class II presentation. Furthermore, inhibition of macroautophagy by RNA silencing of Atg12 inhibited MP1-Atg8 (LC3) transport to vesicles that are MHC class II positive. Taken together, these data suggest that several antigens can enter the MIIC via macroautophagy and that this pathway leads to efficient MHC class II presentation to CD4^+^ T cells.

In addition to macroautophagy, chaperone-mediated autophagy has also been implicated in delivering cytosolic antigens for MHC class II presentation ([Figure 3](#fig3){ref-type="fig"}). The two autoantigens glutamate decarboxylase 65 (GAD65) and the mutant human immunoglobulin κ chain SMA showed enhanced processing onto MHC class II after overexpression of LAMP-2a, the transporter of chaperone-mediated autophagy ([@bib105]). Because MHC class II processing of these antigens also requires proteasomal and calpain-mediated degradation ([@bib59]), Zhou and colleagues suggested that these autoantigens are processed into peptides in the cytosol and then are imported into MIICs by LAMP-2a. Thus, both macroautophagy and chaperone-mediated autophagy can deliver cytosolic and nuclear antigens into MIICs for efficient MHC class II presentation to CD4^+^ T cells. Future studies now need to address to which extent these pathways contribute to CD4^+^ T cell responses in vivo.

Role of Autophagy in CD4^+^ T Cell Immunity and Tolerance {#sec1.6}
---------------------------------------------------------

CD4^+^ T cell stimulation after autophagy-mediated antigen processing could be crucial both during steady-state tolerance induction and immune control of pathogens and tumors. Self-antigen presentation on MHC class II of both thymic epithelial cells and dendritic cells could lead to central and peripheral tolerance maintenance in the CD4^+^ T cell compartment. In agreement with this hypothesis, thymic epithelia display great amounts of autophagosomes in the GFP-LC3 transgenic macroautophagy reporter mouse in the steady state ([@bib69]). Interestingly, more autophagosomes could be found in this tissue in newborns than in adult mice. These findings correlate with T cell selection and central tolerance induction for CD4^+^ T cells being most active at a young age ([@bib94]). In addition, we find considerable autophagy in immature dendritic cells ([@bib90]), which have been implicated in peripheral tolerance induction ([@bib95]). Some of these tolerance mechanisms might be compromised in patients with mutations in Atg16 and Crohn disease ([@bib37], [@bib88]). This inflammatory bowel disease occurs in individuals with genetic predisposition and is probably triggered by the enteric microflora. Therefore, decreased macroautophagy due to Atg16 mutations might either impair innate resistance to invading bacteria in intestinal epithelial cells and thereby trigger inflammation as a result of increased antigenic load or lead to insufficient tolerance induction against commensals in the gut and trigger Crohn disease. On the basis of these findings, it is tempting to speculate that macroautophagy might contribute to self-antigen presentation during central and peripheral tolerance maintenance for CD4^+^ T cells.

CD4^+^ T cells are crucial orchestrators of adaptive immunity. Their activation is required for both B cell differentiation and immunoglobulin maturation during humoral immunity, as well as efficient noninflammatory CD8^+^ T cell priming and maintenance of CD8^+^ T cell function during cell-mediated immunity ([@bib11], [@bib63]). In addition, CD4^+^ T cells can have direct effector functions against infected and transformed cells ([@bib40]). Therefore, autophagic delivery of intracellular antigens for MHC class II presentation could lead to efficient CD4^+^ T cell priming by infected professional antigen-presenting cells, such as dendritic cells. This mechanism could also contribute to CD4^+^ T cell immune surveillance of inflamed tissues, which upregulate MHC class II upon exposure to proinflammatory cytokines ([@bib86]), as we observed for epithelial cells ([@bib90]).

Taken together, the discussed findings show that intracellular antigen processing via autophagy broadens the immunological functions and usefulness of MHC class II presentation. This pathway expands the traditional view that MHC class II presentation is restricted to professional antigen-presenting cells with considerable endocytic activity to the new paradigm that MHC class II molecules also enable immune surveillance and tolerance induction for intracellular antigens during immune activation and in the steady state. Therefore, MHC class II might play a much broader role, similar to MHC class I, at sites of inflammation and MHC class II upregulation.

Autophagy Regulation as an Effector Mechanism of the Adaptive and Innate Immune System {#sec1.7}
--------------------------------------------------------------------------------------

In addition to macroautophagy as an innate immune mechanism in infected host cells, this pathway is also induced as an effector mechanism of innate and adaptive lymphocytes via interferons (IFNs) and members of the tumor necrosis factor (TNF) family ([Figure 3](#fig3){ref-type="fig"}).

Both type I and II IFNs have been reported to modulate macroautophagy. Restriction of HSV-1 infection by macroautophagy in vitro and in vivo was found to be dependent on the type I IFN-inducible double-stranded-RNA-dependent protein kinase R (PKR) ([@bib76], [@bib97]). In order to develop neurovirulence, HSV-1 carries the ICP34.5 protein, which inhibits PKR-dependent macroautophagy induction by binding to Atg6 (Beclin-1) ([@bib76]). Type II IFN has been reported to enhance *Mycobacterium tuberculosis* and *Ricksettia conorii* degradation by macroautophagy in infected cells ([@bib34], [@bib93], [@bib102]). Mouse macrophages seem to be most susceptible to IFN-γ-induced upregulation of macroautophagy, whereas in human tissues, this effect is more difficult to demonstrate and probably proceeds with slower kinetics ([@bib84]). Type II IFN seems to induce macroautophagy and mycobacterial clearance through immunity-related GTPases (IRGs), also known as p47 GTPases, including the mouse LRG-47 and the human IRGM proteins. Mouse tissues are probably more susceptible to this macroautophagy regulation mechanism because their IRGs are IFN-γ inducible, whereas the human IRG is not. In addition, IFN-γ might also induce macroautophagy via death-associated protein kinases (DAPk). Overexpression of DAPk and its close family member DAPk-related protein kinase (DRP)-1 has been shown to increase macroautophagy in human epithelial cell lines ([@bib45]). Irrespective of the exact signaling pathways, these studies suggest that not only infected cells can upregulate macroautophagy via IFN-α and IFN-β but also potent type I IFN producers such as pDCs, as well as IFN-γ-secreting natural killer (NK) and T cells, might induce clearance of intracellular pathogens and enhance MHC class II presentation in infected tissues via this pathway.

Macroautophagy induction via TNF family members has been primarily investigated in cell-death research. The interplay between autophagy and apoptosis underlying these studies has been recently reviewed ([@bib52]). First, TNF-α itself was found to upregulate macroautophagy in cells lacking NF-κB activation ([@bib26]). Second, TNF-related apoptosis-inducing ligand (TRAIL) was described to induce autophagy in human epithelial cells ([@bib65]). Consistent with this, inactivation of Fas-associated death domain (FADD), the signaling adaptor protein of the TRAIL receptor, decreases autophagy induction by TRAIL ([@bib99]). As a third TNF family member, CD40L has been demonstrated to induce macroautophagy-mediated fusion of *Toxoplasma gondii*-containing phagosomes with lysosomes via CD40 signaling on mouse and human macrophages ([@bib7]). RNA silencing of Atg6 (Beclin-1) inhibited CD40-mediated clearance of *T. gondii*. Various cell types of the innate and adaptive immune system could potentially use this macroautophagy induction that is TNF family member mediated, including TNF-α-secreting dendritic cells, TRAIL-expressing NK and T cells, and CD40L-presenting CD4^+^ T cells. However, future studies are required to investigate whether macroautophagy induction during immune responses contributes substantially to resistance against infections in vivo.

Regulation of T Cell Survival and Death by Macroautophagy {#sec1.8}
---------------------------------------------------------

Dendritic cells and NK and T cells might induce macroautophagy in infected cells to fight infections, but at the same time the fate of these immunological effectors seems to be determined by their own capacity to perform macroautophagy. The extent to which this process contributes to cell survival and cell death has so far primarily been investigated in T cells. Although the relationship between autophagy and apoptosis is still not entirely clear, a picture is emerging that autophagy often precedes apoptosis, often as a last rescue attempt before cell death ([@bib52]). In some instances, however, macroautophagy is required for cell death or can even execute it, especially when the apoptosis machinery is compromised. These different modulations of cell death by macroautophagy are also reflected in studies on T cells ([Figure 3](#fig3){ref-type="fig"}). Atg5 deficiency leads to decreased T and B cell numbers in mice, and both CD4^+^ and CD8^+^ T cells fail to undergo efficient proliferation upon T cell receptor stimulation ([@bib83]). These findings were interpreted as macroautophagy playing a role in T cell maintenance during the steady state and after activation. Furthermore, Th2 polarized CD4^+^ T cells, which are thought to support humoral immune responses most efficiently, display more GFP-Atg8 (GFP-LC3)-positive autophagosomes than Th1 cells, which have been shown to support cell-mediated immunity better ([@bib57]). In this study, the Th2 cell line D10 was more resistant to cell death upon growth-factor withdrawal when macroautophagy was inhibited by RNA silencing of Atg7 or Atg6 (Beclin-1), whereas steady-state survival and proliferation were not affected by macroautophagy inhibition. These studies suggest that Th2-polarized CD4^+^ T cells either die by macroautophagy or need the autophagy machinery to execute apoptotic cell death upon growth-factor deprivation. The latter interpretation is more likely because HIV-1 envelope protein induces CD4^+^ T cell apoptosis via macroautophagy and is inhibited upon RNA silencing of Atg7 or Atg6 (Beclin-1) ([@bib30]). According to these studies, macroautophagy seems to be more important for CD8^+^ than CD4^+^ T cell survival, and Th2-polarized CD4^+^ T cells are more sensitive to cell death via macroautophagy than Th1-polarized cells. These data suggest that when manipulating macroautophagy for enhanced pathogen clearance, one should keep in mind that cellular components of the immune system, such as Th2 cells, might be sensitive to cell-death induction via macroautophagy. Therefore, any benefit gained by innate clearance of pathogens in infected cells via macroautophagy enhancement might be lost by compromising another arm of immune control, including Th2-supported humoral immunity.

Conclusions and Future Perspectives {#sec1.9}
-----------------------------------

Previous studies on autophagy in innate and adaptive immune responses have revealed interesting roles for this pathway in innate and adaptive immunity. However, these now need to be investigated in vivo. With the demonstration that macroautophagy inhibition is required for neurovirulence of HSV-1 in mice ([@bib76]), a step into this direction has been taken, but more such in vivo studies need to be performed. In vivo characterizations of the role of autophagy during tolerance induction and in dendritic cells for the initiation of immune responses are of special interest. With conditional knockout mice for essential macroautophagy genes ([@bib38], [@bib51]), siRNAs for silencing Atg genes ([@bib46], [@bib90]), and viral inhibitors of macroautophagy ([@bib76], [@bib78]), these studies become feasible in mice. A second important area is the investigation of substrate characteristics for pathogen and antigen import into autophagosomes. Although ubiquitination has been proposed as an import signal for macroautophagy ([@bib13]), no firm evidence for this hypothesis has been presented. Finally, starvation-independent regulation of autophagy, especially during infections, is just beginning to become unraveled. A better understanding of this process, however, is required to evaluate it for therapeutic potential, especially because macroautophagy can not only support cell survival and pathogen clearance but also cell death. For manipulations of this pathway in patients, one has to walk a fine line between evoking its beneficial effects and avoiding tissue damage.
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